4 years ago

Assessment of chemotherapy on various biochemical markers in breast cancer patients

Geane Felix Souza, Mohammad Zubair Alam, Marcus Vinícius Oliveira Barros Alencar, Kátia Conceição Machado, Muhammad Torequl Islam, Márcia Fernanda Correia Jardim Paz, João Marcelo Castro e Sousa, Juliana Silva, Siddhartha Kumar Mishra, Antonio Luiz Gomes Júnior, Ana Amélia Carvalho Melo-Cavalcante, Nasimudeen R Jabir, Shams Tabrez, Leonardo Fortes Gomes, Keylla Conceição Machado, Eunus S. Ali
Chemotherapy is a standard treatment method for the patients with locally advanced breast cancer. Lately, cyclophosphamide (CYP) and doxorubicin (DOX) are used as the major chemotherapeutic agents. Till date, no serum biomarker has been able to provide an early diagnosis of breast cancer. This study aimed to assess inflammatory, cardiac, renal and hematological markers in 56 breast cancer patients (BCP) before, during and after termination of chemotherapy with CYP and DOX. Blood samples were collected from the patients at the each treatment stages mentioned above. These samples were assessed for interleukin 6 (IL-6), interleukin 10 (IL-10), lactate dehydrogenase (LDH), creatine kinase (CK), creatinine, hemoglobin (Hb), leukocyte, platelet and Na+/K+-ATPase levels by either ELISA or colorimetric methods. The results suggest a significant increase in IL-6 level at all the stages in BCP as compared to control group. On the other hand, IL-10, CK and Na+/K+-ATPase levels were significantly declined during all the stages. Moreover, the majority of hematological parameters remained unchanged throughout the treatment period with the exception of creatinine and hemoglobin which showed modulation in their level at different stages. Based on the results, we conclude that breast cancer and co-treatment of CYP and DOX interfere with various biological markers, thereby, showing the physiological imbalance. This article is protected by copyright. All rights reserved

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/jcb.26487

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.